NCT03838120

Brief Summary

Peripheral nerve blocks with use of USG allowed visualisation of the structures and nerves and made the block administrations safe, quick and comfortable. However there are few publications concerning the minimum local anesthetic volume capable of providing blocks. In this study the investigastors aimed to find Minimum Effective Volume Of Local Anesthetic For Ultrasound-Guided İnfraclavicular Approach for Brachial Plexus Blockade in upper limb operations.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
48

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Nov 2015

Shorter than P25 for phase_4

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2015

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2016

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2016

Completed
2.3 years until next milestone

First Submitted

Initial submission to the registry

February 10, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

February 12, 2019

Completed
Last Updated

October 27, 2021

Status Verified

February 1, 2019

Enrollment Period

5 months

First QC Date

February 10, 2019

Last Update Submit

October 20, 2021

Conditions

Keywords

UltrasoundMinimumInfraclavicular block

Outcome Measures

Primary Outcomes (1)

  • minimum effective volume

    Determining the minimum effective volume of bupivacaine 0,5% for successful ultrasound guided infraclavicular brachial plexus block for upper limb surgery

    A blinded Assistant assess sensory and motor blockade in a 5-min intervals up to 60 minutes.

Secondary Outcomes (4)

  • Successful blockade onset time

    A blinded Assistant assess sensory and motor blockade in a 5-min intervals up to 60 minutes.

  • Regression time of sensorial blockade

    post-op 2, 4, 8, 12, 16, and 24 hours.

  • Regression time of motor blockade

    post-op 2, 4, 8, 12, 16, and 24 hours.

  • Time of first additional analgesic requirement

    The post-operative pain of patients was evaluated via the visual analogue scale (VAS) at post-op 2, 4, 8, 12, 16, and 24 hours

Study Arms (1)

Bupivacaine 0,5% Single arm study

OTHER

Bupivacaine 0,5% Single arm study

Other: Procedure/Surgery: bupivakain % 0,5

Interventions

In this study, 5 patients were included in each volume group and at least 3 applications out of 5 had to be successful to consider the volume to be sufficient. After a successful group, the volume was reduced by 2 ml's and the same procedure was followed until a final group with unsuccessful anesthesia was found (≤2 successful blockades). The study was ended at this point and MEV was determined as the volume used in the last successful group. The researcher which determined the success of blockade was blinded to the study protocol. BMI, ASA Score, Successful blockade onset time Regression time of sensorial blockade Regression time of motor blockade Time of first additional analgesic requirement

Bupivacaine 0,5% Single arm study

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients between 18-70 years of age who were determined as ASA I-III and underwent upper limb surgery from November 2015 to November 2016 and provided informed consent, were included in the study.

You may not qualify if:

  • Patients who had any of the following conditions were excluded: ASA risk score of IV or V, serious cardiac, respiratory, hepatic or renal comorbidities, mental disorder, coagulopathy, pregnancy, local anesthetic allergy, neuromuscular and/or neurological disease, and infection at the site of injection. Patients who were unwilling to participate were also excluded

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NA
Masking
NONE
Purpose
PREVENTION
Intervention Model
SEQUENTIAL
Model Details: A total of 48 ASA I-II patients underwent upper limb surgery operation by administering USG guided-infraclavicular blockage were included in the study. brachial plexus were seen and the minimum effective LA volume was investigated starting with total 30 ml of %0.5 bupivacain. After accomplishing the blockage, volume was decreased 2ml. Block administration time, block onset times, anesthesia times and time to first analgesic requirement were recorded.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 10, 2019

First Posted

February 12, 2019

Study Start

November 1, 2015

Primary Completion

April 1, 2016

Study Completion

November 1, 2016

Last Updated

October 27, 2021

Record last verified: 2019-02